Determinants of endothelial dysfunction and carotid intima-media thickness in combined hyperlipidemia

Coronary Artery Disease

Volumn 16, Issue 3, 2005, Pages 175-180

  Šebeštjen, Miran ^a,b   Žegura, Branka ^a   Videčnik, Viktor ^a   Keber, Irena ^a  

^a Trnovo Hospital of Internal Medicine   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Carotid intima media thickness; Combined hyperlipidemia; Flow mediated dilation

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; CYTOKINE; GLUCOSE; INTERLEUKIN 6; LIPOPROTEIN; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTERY DILATATION; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; BRACHIAL ARTERY; CAROTID ARTERY; ENDOTHELIUM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ADULT; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; BRACHIAL ARTERY; CAROTID ARTERIES; ENDOTHELIUM, VASCULAR; HUMANS; HYPERLIPIDEMIAS; INTERLEUKIN-6; LIPOPROTEINS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGIONAL BLOOD FLOW; TUMOR NECROSIS FACTOR-ALPHA; TUNICA INTIMA; TUNICA MEDIA; VASODILATION;

EID: 17844410375     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200505000-00007     Document Type: Article

References (49)

1. Celermajer DS. Endothelial dysfunction: Does it matter? Is it reversible? J Am Coll Cardiol 1997; 30:325-333.
2. Grundy SM. Hypertrigliceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998; 81(suppl 4A):18B-25B.
3. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101:1899-1906.
4. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106:653-658.
5. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101:948-954.
6. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315:1046-1031.
7. Chowienczyk PJ, Watts GF, Cockcroft JR, Ritter JM. Impaired endothelium-dependent vasodilatation of forearm resistance vessels in hypercholesterolemia. Lancet 1992; 340:1430-1432.
8. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323:22-27.
9. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993; 88:2149-2155.
10. Steinberg HO, Bayazeed B, Hook G, Johnson A, Cronin J, Baron AD. Endothelial dsyfunction is associated with cholesterol levels in the high normal range in humans. Circulation 1997; 96:3287-3293.
11. Chambers JC, Obeid OA, Kooner JS. Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. Arterioscler Thromb Vasc Biol 1999; 19:2922-2927.
12. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102:1000-1006.
13. Nawawi H, Osman NS, Annuar R, Khalid BA, Yusoff K. Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. Atherosclerosis 2003; 169:283-291.
14. Furumoto T, Fujii S, Saito N, Mikami T, Kitabatake A. Relationships between brachial artery flow mediated dilation and carotid artery intima-media thickness in patients with suspected coronary artery disease. Jpn Heart J 2002; 43:117-125.
15. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96:1432-1437.
16. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340:14-22.
17. Ylitalo K, Syvanne M, Salonen R, Nuotio I, Taskinen MR, Salonen JT. Carotid artery intima-media thickness in Finnish families with familial combined hyperlipidemia. Atherosclerosis 2002; 162:171-178.
18. Keulen ET, Kruijshoop M, Schaper NC, Hoeks AP, de Bruin TW. Increased intima-media thickness in familial combined hyperlipidemia associated with apolipoprotein B. Arterioscler Thromb Vasc Biol 2002; 22:283-288.
19. Winbeck K, Kukla C, Poppert H, Klingelhofer J, Conrad B, Sander D. Elevated C-reactive protein is associated with an increased intima to media thickness of the common carotid artery. Cerebrovasc Dis 2002; 13:57-63.
20. Del Rincon I, Williams K, Stern MP, Freeman GL, O'Leary DH, Escalante A. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003; 48:1833-1840.
21. Leonsson M, Hulthe J, Johannsson G, Wiklund O, Wikstrand J, Bengtsson BA, et al. Increased interleukin-6 levels in pituitary-deficient patients are independently related to their carotid intima-media thickness. Clin Endocrinol 2003; 59:242-250.
22. Friedwald WT, Levy Rl, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
23. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International federation of clinical chemistry standardization project for measurements of apolipoproteins A1 and B. Clin Chem 1994; 40:586-592.
24. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998; 98:1487-1494.
25. Brandsom A, Johnson O, Dahlén GH, Rönby M. Lp(a) levels in healthy population measured by a new enzyme linked immunosorbent assay. Thromb Haemost 1989; 62:573.
26. Müllner S, Neubauer H, König W. A radioimmunoassay for the determination of insulins from several animal species, insulin derivatives and insulin precursors in both their native and denatured state. J lmmunol Meth 1991; 140:211-218.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and ß-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
28. Roberts WL, Sedrick R, Moulton L, Spencer A, Rifai N. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem 2000; 46:461-468.
29. Šebeštjen M, Žegura B, Keber I. Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidemia. J Intern Med 2002; 251:77-85.
30. Ayyobi AF, McGladdery SH, McNeely MJ, Austin MA, Motulsky AG, Brunzell JD. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2003; 23:1289-1294.
31. Iribarren C, Folsom AR, Jacobs DR Jr, Gross MD, Belcher JD, Eckfeldt JH. Association of serum vitamin levels, LDL susceptibility to oxidation, and autoantibodies against MDA-LDL with carotid atherosclerosis. A case-control study, The ARIC Study Investigators. Atherosclerosis Risk in Communities. Arterioscler Thromb Vasc Biol 1997; 17:1171-1177.
32. Heitzer T, Yla-Herttuala S, Luoma J, Kurz S, Munzel T, Just H et al. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. Circulation 1996; 93:1346-1353.
33. Salonen JT, Nyyssonen K, Salonen R, Porkkala-Sarataho E, Tuomainen TP, Diczfalusy U, et al. Lipoprotein oxidation and progression of carotid atherosclerosis. Circulation 1997; 95:840-845.
34. Hulthe J, Bokemark L, Fagerberg B. Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol 2001; 21:101-107.
35. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Circulation 1995; 91:284-290.
36. Meade TW, Ruddock V, Stirling Y, Chakrabarti T, Miller GJ. Fibrinolytic activity, clotting factors and long-term incidence of isheamic heart disease in the Northwick Park Heart Study. Lancet 1993; 342:1076-1079.
37. Lindahl AK. Tissue factor pathway inhibitor: from unknown coagulation inhibitor to major antithrombotic principle. Cardiovasc Res 1997; 33:286-291.
38. Broze GJ Jr. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinol 1995; 6:S7-S13.
39. Folsom AR. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost 2001 ; 86:366-373.
40. Morishita E, Asakura H, Saito M, Yamazaki M, Ontachi Y, Mizutani T, et al. Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients. Atherosclerosis 2001; 154:203-212.
41. Furumoto T, Fujii S, Saito N, Mikami T, Kitabatake A. Relationships between brachial artery flow mediated dilation and carotid artery intima-media thickness in patients with suspected coronary artery disease. Jpn Heart J 2002; 43:117-125.
42. Vakkilainen J, Makimattila S, Seppala-Lindroos A, Vehkavaara S, Lahdenpera S, Groop PH, et al. Endothelial dysfunction in men with small LDL particles. Circulation 2000; 102:716-721.
43. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101:1767-1772.
44. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101:2149-2153.
45. Walsh BW, Cox DA, Sashegyi A, Dean RA, Tracy RP, Anderson PW. Role of tumor necrosis factor-α and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 2001; 88:825-828.
46. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102:1000-1006.
47. Bhagat K, Collier J, Vallance P. Endothelial stunning following a brief exposure to endotoxin: a mechanism to link infection to infarction? Cardiovasc Res 1996; 32:822-829.
48. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387-1397.
49. Juonala M, Viikari JSA, Laitinen T, Marniemi J, Helenius H, Roennemma T, et al. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults. Circulation 2004; 110:2918-2923.